Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
Starting in the 1950s, study and elucidation of the biochemical mechanisms of resistance to antibiotics led to the understanding of both the biology of bacteria and the mode of action of antibiotics. This holds true for the relationship between Streptococcus pneumoniae and the fluoroquinolones. A new feature in this approach is the availability of the nearly complete chromosome sequence of this major human pathogen. In S. pneumoniae, resistance appears to be mainly due to mutational alterations in the intracellular targets of the fluoroquinolones, the type II DNA topoisomerase gyrase and topoisomerase IV. Both enzymes appear to be the primary targets of the drugs in this species. Mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene or the parC gene, which encode the A subunits of DNA gyrase and topoisomerase IV respectively, confer resistance to single-step mutants. Mutations in gyrB and parE, which encode the B subunits of DNA gyrase and topo IV, respectively, have also been implicated in the fluoroquinolone resistance of certain mutants obtained in vitro. The antibiotics most affected by a single mutation are those for which the mutation occurs in their preferred target e.g. gyrase for sparfloxacin and gatifloxacin and topo IV for ciprofloxacin and levofloxacin. The activity of all fluoroquinolones is decreased further when two or more mutations are present. Because they possess similar targets of action, there is cross resistance, albeit at various degrees depending on the intrinsic activity of the molecule, among fluoroquinolones. This stresses, once more, the misleading concept of breakpoints for clinical categorization. A second mechanism of resistance, enhanced active efflux of hydrophilic quinolones such as norfioxacin and ciprofloxacin, is mediated by the membrane-associated protein, PmrA (pneumococcal multidrug resistance). This protein is a 12-transmembrane segment proton-dependent multidrug efflux pump of the major facilitator family. The combinatorial approach of bacteria to fluoroquinolone resistance implies that the molecule actually used, as well as a less active member of the class that is more apt to detect resistance mechanisms (e.g. ciprofloxacin), should be tested in vitro.
Harding
I
I
Micron Research, Marmont Priory Farm, Upwell, Cambs, UK. ianharding@ndirect.co.uk
Simpson
I
I
D000890:Anti-Infective Agents / Q000378:metabolism / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000187:drug effects* / Q000235:genetics; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II / Q000187:drug effects* / Q000235:genetics; D004352:Drug Resistance, Microbial / Q000235:genetics; D024841:Fluoroquinolones; D006801:Humans; D017354:Point Mutation; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics
D000890:Anti-Infective Agents; D001426:Bacterial Proteins; D024841:Fluoroquinolones; D027101:DNA Topoisomerase IV; D004250:DNA Topoisomerases, Type II